Phase 1a1b Study of LY4170156, an Antibody-Drug Conjugate, for Treating Selected Advanced Solid Tumors Including Ovarian, Endometrial, Cervical, Lung, Breast, Pancreatic, and Colorectal Cancers

What this Trial Is About

Researchers are evaluating LY4170156, an antibody-drug conjugate targeting folate receptor alpha-expressing tumor cells, in participants with selected advanced solid tumors. This phase 1a1b trial aims to assess the safety, tolerability, and preliminary effectiveness of LY4170156 given alone or in combination with other drugs such as bevacizumab, carboplatin, pembrolizumab, and itraconazole. The study includes dose escalation, dose optimization, and dose expansion parts and is expected to last up to approximately 4 years. Participants receive LY4170156 administered intravenously at escalating or optimized doses. Some groups receive the drug alone, while others receive it combined with bevacizumab, carboplatin, pembrolizumab, or itraconazole oral. The trial compares different doses during dose escalation and evaluates the recommended phase 2 dose. Treatment cycles are generally 21 days in length. During the study, participants undergo regular monitoring for safety and tumor response. Researchers assess outcomes such as the recommended phase 2 dose, overall response rate, duration and time to response, progression-free survival, and disease control rate. Pharmacokinetics of LY4170156 alone and in combination are also studied. Monitoring for serious adverse events related to the drug occurs throughout the study, which may last up to 4 years per participant.

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors